Bayer AG (BAYZF)
57.35
+1.18
(+2.09%)
USD |
OTCM |
Aug 25, 16:00
Bayer Enterprise Value : 95.52B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 95.52B |
| August 24, 2026 | 94.36B |
| August 21, 2026 | 94.14B |
| August 20, 2026 | 94.61B |
| August 19, 2026 | 92.83B |
| August 18, 2026 | 92.83B |
| August 17, 2026 | 92.83B |
| August 14, 2026 | 92.83B |
| August 13, 2026 | 92.83B |
| August 12, 2026 | 94.15B |
| August 11, 2026 | 95.06B |
| August 10, 2026 | 95.06B |
| August 07, 2026 | 95.06B |
| August 06, 2026 | 95.06B |
| August 05, 2026 | 95.20B |
| August 04, 2026 | 93.86B |
| August 03, 2026 | 92.36B |
| July 31, 2026 | 93.45B |
| July 30, 2026 | 93.97B |
| July 29, 2026 | 91.97B |
| July 28, 2026 | 91.05B |
| July 27, 2026 | 91.05B |
| July 24, 2026 | 91.05B |
| July 23, 2026 | 91.05B |
| July 22, 2026 | 93.17B |
| Date | Value |
|---|---|
| July 21, 2026 | 93.17B |
| July 20, 2026 | 93.17B |
| July 17, 2026 | 93.17B |
| July 16, 2026 | 93.17B |
| July 15, 2026 | 93.17B |
| July 14, 2026 | 94.19B |
| July 13, 2026 | 94.55B |
| July 10, 2026 | 95.08B |
| July 09, 2026 | 95.96B |
| July 08, 2026 | 95.07B |
| July 07, 2026 | 96.70B |
| July 06, 2026 | 96.70B |
| July 02, 2026 | 98.12B |
| July 01, 2026 | 93.45B |
| June 30, 2026 | 93.21B |
| June 29, 2026 | 89.76B |
| June 26, 2026 | 90.41B |
| June 25, 2026 | 91.24B |
| June 24, 2026 | 81.64B |
| June 23, 2026 | 81.64B |
| June 22, 2026 | 80.74B |
| June 18, 2026 | 81.87B |
| June 17, 2026 | 81.87B |
| June 16, 2026 | 78.80B |
| June 15, 2026 | 79.00B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck KGaA | 33.00B |
| Breakthrough Chemistry, Inc. | 1.389M |
| Cardiac Biotech Solutions, Inc. | 7.343M |
| Fresenius SE & Co. KGaA | 42.56B |
| Carl Zeiss Meditec AG | 3.351B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 266.26M |
| Revenue (Quarterly) | 12.64B |
| Total Expenses (Quarterly) | 12.39B |
| EPS Diluted (Quarterly) | 0.2592 |
| Gross Profit Margin (Quarterly) | 58.24% |
| Profit Margin (Quarterly) | 2.11% |
| Earnings Yield | -3.57% |
| Operating Earnings Yield | 12.98% |
| Normalized Earnings Yield | 3.445 |